Лучшие больницы для «Breast Lift Surgery» в ОАЭ

The cost of Breast Lift Surgery (Mastopexy) depends significantly on the surgical technique selected, whether it is combined with breast augmentation (implants or fat grafting), the specific hospital tier, and the surgeon's level of expertise. In India, at NABH- and JCI-accredited hospitals partnered with GAF Healthcare, the total cost of an isolated mastopexy (including surgeon fees, anaesthesiologist, operating theatre, 1–2 nights hospital stay, standard post-operative medications, and compression brassiere) ranges from approximately USD $1,800 to $4,500. Augmentation-mastopexy (with silicone implants) typically adds USD $800–$2,000 to these figures for implant cost. In the UAE (Dubai and Abu Dhabi), at JCI- and DHA/DoH-accredited private hospitals, the same procedure ranges from approximately USD $4,000 to $9,000 for isolated mastopexy, reflecting the premium private healthcare infrastructure, luxury patient-accommodation standards, and higher operating costs of the Gulf market. India is therefore typically 40–60% more affordable than the UAE for equivalent surgical outcomes. GAF Healthcare provides a personalised cost estimate inclusive of all clinical and logistical components before any financial commitment is made by the patient.

The minimum recommended in-country stay after Breast Lift Surgery (Mastopexy) is 2 weeks (14 days) from the date of surgery before undertaking a short- or medium-haul flight (under 6 hours). For long-haul intercontinental flights (6 hours or more — for example, India to the UK, UAE to Australia, or India to Canada), the operating surgeon's clinical clearance is required, and this is typically not issued until at least 3–4 weeks post-operatively. The reasons for this timeline are clinically specific: in the first 2 weeks, the risk of wound dehiscence at tension points (particularly the T-junction in Wise-pattern/anchor mastopexy) remains elevated; cabin pressure changes and prolonged immobility at altitude increase the risk of deep vein thrombosis (DVT), especially in patients who have undergone general anaesthesia; and swelling (oedema) and bruising must be stable enough that any new symptoms can be clinically distinguished from early complications. GAF Healthcare's operating surgeon issues a formal 'Fit to Fly' certificate at the final pre-departure wound review (typically Day 10–14). Patients are advised not to pre-book non-refundable return flights for fewer than 14 days post-surgery, and to purchase travel insurance that covers post-operative medical eventualities. For augmentation-mastopexy (combined implant and lift surgery), the minimum in-country stay is extended to 3 weeks given the additional dissection and recovery requirements.

Breast Lift Surgery (Mastopexy) has a high patient satisfaction rate of 91–95% in peer-reviewed outcome studies and in BREAST-Q validated post-operative surveys conducted at high-volume plastic surgery centres. 'Success' in mastopexy is defined by multiple parameters: achievement of the planned nipple-areola complex (NAC) elevation to the target position (typically 19–21 cm from sternal notch), maintenance of breast shape and projection at 12 months, scar quality scoring, and patient-reported quality-of-life improvement. The overall surgical complication rate at JCI/NABH/DHA-accredited centres is below 5% for major complications (haematoma, wound infection, NAC compromise) and approximately 8–12% for minor complications (temporary sensory change, minor wound healing delay). In terms of longevity, mastopexy results are durable but not permanent — gravitational effects, ageing, hormonal changes, and fluctuations in body weight will continue to act on the breast over time. Studies show that at 5 years, approximately 85% of patients maintain a clinically satisfactory result. Durability is significantly enhanced by: maintaining stable body weight, avoiding future pregnancy (or understanding that pregnancy may reverse the result), using a supportive brassiere during high-impact activities, and — where an internal GalaFLEX P4HB bioabsorbable scaffold was used — the collagen matrix reinforcement laid down during mesh resorption provides additional long-term parenchymal support beyond what skin closure alone achieves. Patients with severe Grade III ptosis and significantly lax, thin skin have a higher risk of re-ptosis over time and should be counselled on this by their surgeon during the pre-operative consultation facilitated by GAF Healthcare.